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The role of natural CD4
 
 
 
CD25
 
 
 
 regulatory T (T reg) cells in the control of allergic asthma 
remains poorly understood. We explore the impact of T reg cell depletion on the allergic 
response in mice susceptible (A/J) or comparatively resistant (C3H) to the development of 
allergen-induced airway hyperresponsiveness (AHR). In C3H mice, anti-CD25–mediated T reg 
cell depletion before house dust mite treatment increased several features of the allergic 
diathesis (AHR, eosinophilia, and IgE), which was concomitant with elevated T helper type 2 
(Th2) cytokine production. In similarly T reg cell–depleted A/J mice, we observed a moderate 
increase in airway eosinophilia but no effects on AHR, IgE levels, or Th2 cytokine synthesis. 
As our experiments suggested that T reg cell depletion in C3H mice before sensitization was 
sufficient to enhance the allergic phenotype, we characterized dendritic cells (DCs) in T reg 
cell–depleted C3H mice. T reg cell–depleted mice had increased numbers of pulmonary myeloid 
DCs with elevated expression of major histocompatibility complex class II, CD80, and CD86. 
Moreover, DCs from T reg cell–depleted mice demonstrated an increased capacity to stimulate 
T cell proliferation and Th2 cytokine production, which was concomitant with reduced IL-12 
expression. These data suggest that resistance to allergen-driven AHR is mediated in part by 
CD4
 
 
 
CD25
 
 
 
 T reg cell suppression of DC activation and that the absence of this regulatory 
pathway contributes to susceptibility.
 
Allergic asthma is a chronic inflammatory disease
of the lung whose incidence and morbidity con-
tinues to rise in developed nations. Asthma is
thought to occur as a result of inappropriate
type 2–dominated immune responses to other-
wise innocuous environmental allergens. In
particular, type 2 cytokines (i.e., IL-4, IL-5,
and IL-13) have been shown to regulate the
pathological features of disease, including air-
way hyperresponsiveness (AHR), eosinophilic
pulmonary inflammation, airway wall remod-
eling, and IgE synthesis (1). Despite an increas-
ingly sophisticated understanding of the role of
these cytokines in disease pathogenesis, the
mechanism underlying the development of
skewed T helper type 2 (Th2) immune responses
in certain individuals remains unknown. An
improved understanding of the mechanisms of
regulation of T cell activity in allergic disease
may lead to the development of effective ther-
apeutic strategies for the treatment of this debil-
itating disease.
Regulatory T (T reg) cells are T cells
functionally distinguished by their capacity to
limit T cell proliferation and effector function
(2, 3). Although there is extensive evidence
that T reg cells play a major role in controlling
autoimmune responses (4), studies exploring
the role of T reg cells in allergic disease have
primarily focused on inducible T reg cells
(referred to as Tr1 or Th3 cells). In humans,
the reduction of allergic symptoms after success-
ful allergen immunotherapy was associated with
the appearance of IL-10–producing T reg
cells (5, 6). In animal studies, a population of
CD4
 
 
 
 T cells induced by OVA (alum) immuni-
zation has been shown to inhibit the develop-
ment of IgE responses (7). Inhalational tolerance
is also mediated by ICOS/ICOS-L–driven
expansion of IL-10–producing T reg cells (8).
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Additionally, exposure to inhaled allergen before systemic
sensitization induces decreased IgE synthesis and airway eo-
sinophilia by promoting the development of CD4
 
 
 
 T reg
cells expressing surface-bound TGF-
 
 
 
 (9). Interestingly, ex-
posure to heat-killed 
 
Mycobacterium vaccae
 
 gives rise to a pop-
ulation of IL-10– and TGF-
 
 
 
–producing T reg cells that
limit synthesis of IgE, type 2 cytokine production, and AHR
after subsequent allergen exposure (10). In a similar manner,
systemic allergen sensitization in the presence of killed 
 
Liste-
ria monocytogenes
 
 markedly reduces airway inflammation and
AHR by facilitating the development of a unique population
of T reg cells that produce IL-10 and IFN-
 
 
 
 and express
ICOS, T-bet, and Foxp3 (11). Collectively these studies pro-
vide compelling evidence that induction of T reg cell popu-
lations (Tr1, Th3, or Th1-like Tr cells) can facilitate the
suppression of allergic inflammation and AHR through in-
creased IL-10 and/or TGF-
 
 
 
 production.
Naturally occurring regulatory cells are a distinct, thy-
mus-derived population of regulatory CD4
 
 
 
 T cells that
constitutively express the IL-2 receptor 
 
 
 
 chain, CD25.
Expression of Foxp3, a forkhead transcription factor in-
duced early in thymic T cell development after TCR–
MHC interactions confers regulatory activity to the CD4
 
 
 
CD25
 
 
 
 T cell population (12). In contrast to the consis-
tently reported inhibitory effect of inducible T reg cells on
allergic responses, the few studies exploring the importance
of naturally occurring T reg cells in control of allergic dis-
ease have yielded conflicting data. Although the develop-
ment of AHR is consistently unaffected by altering the
number of CD4
 
 
 
CD25
 
 
 
 T reg cells present (13, 14), the
development of eosinophilic airway inflammation is re-
ported to be both increased (13) and, paradoxically, de-
creased (15) after depletion of naturally occurring CD4
 
 
 
CD25
 
 
 
 T reg cells. Interestingly, the role of naturally oc-
curring T reg cells has only been evaluated in strains of
mice that are genetically predisposed to the development of
experimental asthma, which may confound determination
of the role they normally play in controlling the develop-
ment of allergic asthma in genetically resistant hosts.
In this paper, we determined the extent to which natu-
rally occurring T reg cells limit the development of experi-
mentally induced asthma in mice genetically predisposed (A/J)
or comparatively resistant (C3H/HeJ) to the development of
AHR. We find that in vivo depletion of natural CD4
 
 
 
CD25
 
 
 
 T reg cells in resistant animals before initial antigen
contact increases AHR, airway eosinophilia, IgE synthesis,
and is concomitant with type 2 cytokine production. De-
spite effective in vivo depletion of T reg cells and an equiva-
Figure 1. Increased bronchial hyperresponsiveness and airway 
inflammation in anti-CD25–treated C3H mice. A/J and C3H animals 
were sensitized and challenged with PBS or HDM as described in Materials 
and methods. HDM-treated animals were treated with isotype control 
mAb (HDM Iso) or anti-CD25 (HDM aCD25) throughout the protocol. AHR 
of A/J (A) and C3H (B) mice was measured. Total (C) and differential (D) 
BALF cell counts. Data represent means   SEM (n   20 mice/group). 
* or **, P   0.05 or P   0.001, respectively, compared with PBS-sensitized/
challenged animals; † or ††, P   0.05 or P   0.001, respectively, compared 
with HDM isotype–treated animals. 
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lent ability of T reg cells from susceptible mice to suppress T
effector function in vitro, T reg cell depletion has no effect
on allergen-driven AHR in the A/J mice. Enhancement of
the allergic phenotype in T reg cell–depleted C3H mice is
associated with an enhanced ability of pulmonary DCs to
stimulate T cell proliferation and Th2 cytokine production
in vitro and an up-regulation of MHC class II and co-stimu-
latory molecule expression on the myeloid DC (mDC) pop-
ulation. Thus, we conclude that naturally occurring CD4
 
 
 
CD25
 
 
 
 T reg cells exert their suppressive effects in vivo not
through direct effects on T cells, but rather by limiting DC
activation.
 
RESULTS
T reg cell depletion renders normally resistant C3H mice 
susceptible to the development of AHR
 
To directly assess the importance of T reg cells in the control
of experimentally induced asthma, we examined AHR in T
reg–depleted allergen-sensitized and -challenged mice sus-
ceptible (A/J) or resistant (C3H) to the development of al-
lergen-induced AHR (16). To deplete T reg cells through-
out the duration of the experiment, mice were treated with
the T reg cell–depleting anti-CD25 mAb PC61 (17, 18) or
an isotype control before sensitization (day –2) and during
the effector phase (day 12) of the immune response. As
shown in Fig. 1 A, intratracheal (i.t.) house dust mite
(HDM) instillation in isotype-treated A/J mice resulted in a
greater than eightfold increase in AHR compared with PBS-
treated animals. Anti-CD25 treatment did not significantly
alter AHR levels in A/J mice (Fig. 1 A). In contrast, although
HDM exposure increased AHR approximately threefold in
C3H mice, anti-CD25 treatment resulted in an additional
75% increase in AHR above that seen in C3H mice treated
with control mAb (Fig. 1 B). These results suggest that natu-
ral T reg cells normally exert regulatory control that limits
the development of allergen-induced AHR in resistant but
not susceptible mice.
To examine the effects of T reg cell depletion on allergen-
induced pulmonary inflammation, bronchoalveolar lavage fluid
(BALF) was collected and cell counts were performed. In both
A/J and C3H mice exposed to i.t. HDM, a dramatic increase
in BALF cellularity was seen (Fig. 1 C), of which eosinophils
constituted 65 and 55% in A/J and C3H animals, respectively
(Fig. 1 D). Depletion of T reg cells resulted in a significant in-
crease in the number of eosinophils in the BALF of both A/J
and C3H anti-CD25–treated mice compared with those re-
ceiving isotype control mAb (70 and 120% increases in A/J and
C3H mice, respectively; Fig. 1 D). Significant increases in
BALF macrophage and lymphocyte numbers were also seen in
anti-CD25–treated C3H and A/J mice, respectively (Fig. 1 D).
Figure 2. T reg cell depletion increases intensity of immune responses 
in C3H but not A/J animals. A/J and C3H animals were sensitized and 
challenged with PBS or HDM as described in Materials and methods. 
HDM-treated animals were treated with isotype control mAb (HDM Iso) or 
anti-CD25 (HDM aCD25) throughout the protocol. Serum levels of total 
IgE (A) and HDM-specific IgE (B) were measured by ELISA at death, 72 h 
after final HDM challenge. Production of IL-4 (C), IL-5 (D), IL-10 (E), and 
IL-13 (F), measured by ELISA, of lung cells cultured ex vivo for 72 h in the 
presence of 30  g/ml HDM extract. Data represent means   SEM (n   20 
mice/group). * or **, P   0.05 or P   0.001, respectively, compared with 
PBS-sensitized/challenged animals; † or ††, P   0.05 or P   0.001, respec-
tively, compared with HDM isotype–treated animals. 
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It is particularly interesting to note that anti-CD25 treatment of
both strains of mice resulted in enhanced eosinophilia (albeit
not as dramatically in the A/J mice), yet only C3H mice had a
concomitant increase in AHR. This suggests that there is a dis-
association between control of eosinophilic inflammation and
AHR by natural CD4
 
 
 
CD25
 
 
 
 T reg cells.
 
Depletion of T reg cells enhances IgE synthesis and Th2 
cytokine production in resistant mice
 
To measure the impact of T reg cell depletion on in vivo pro-
duction of IgE, animals were bled immediately before death
for measurement of total and HDM-specific IgE levels. Both
A/J and C3H mice exposed to HDM produced elevated levels
of total (Fig. 2 A) and HDM-specific IgE in comparison with
their respective controls (Fig. 2 B). Although levels of total and
HDM-specific IgE were similar in anti-CD25– and control
mAb–treated A/J mice, there was a dramatic increase in IgE
production in T reg cell–depleted C3H mice compared with
C3H mice treated with control antibodies (Fig. 2, A and B).
As the pathophysiological manifestations of allergic asthma
are typically accompanied by robust Th2 immune responses,
we next examined the effect of T reg cell depletion on the in-
tensity of the HDM-specific type 2 immune response. To
measure the intensity of the allergic response in anti-CD25–
treated A/J and C3H mice, we examined HDM-stimulated
cytokine production in whole lung cell cultures. Lung cells
from HDM-sensitized and -challenged A/J and C3H mice
both produced readily detectable quantities of the type 2 cy-
tokines IL-4, IL-5, IL-10, and IL-13 upon in vitro HDM
restimulation (Fig. 2, C–F). In cultures from A/J mice, HDM-
stimulated type 2 cytokine production from anti-CD25–
treated cells was indistinguishable from that seen in cultures
from control mice (Fig. 2, C–F). In contrast, production of
IL-5 and IL-13 was significantly increased in lung cultures
from anti-CD25–treated C3H mice (Fig. 2, D and F). Al-
though there was also clearly elevated IL-4 and IL-10 produc-
tion in cultures from anti-CD25–treated C3H mice, these val-
ues did not reach statistical significance (Fig. 2, C and E).
IFN-
 
 
 
 production was undetectable in HDM-stimulated lung
cell cultures from both strains of mice under all conditions
demonstrating a strong type 2 bias of the immune response
(unpublished data). Thus, although natural CD4
 
 
 
CD25
 
 
 
 T
reg cells have the capacity to limit airway eosinophilia in both
strains of animals, other parameters of the asthmatic response
such as IgE synthesis, type 2 cytokine production, and AHR
are only under the regulatory control of T reg cells in geneti-
cally resistant animals. These results suggest that resistance to
the development of asthma may result from a population of
CD4
 
 
 
CD25
 
 
 
 T reg cells with a more potent regulatory ca-
pacity or that “target” cells from resistant individuals are
uniquely sensitive to the suppressive influence of T reg cells.
 
Failure of anti-CD25 treatment of A/J mice to enhance 
immunity is not caused by incomplete T reg cell depletion
 
To determine whether the differences in the effect of T reg
cell depletion on the allergic response in the two strains is
caused by differences in the numbers of T reg cells in the
lungs, we examined the numbers of T reg cells in the lungs of
susceptible A/J and resistant C3H mice. Flow cytometry ex-
periments confirmed that the lungs of naive C3H and A/J
mice contained similar numbers of CD4
 
 
 
CD25
 
bright
 
 cells (T
reg cells) and CD4
 
 
 
CD25
 
dim
 
 cells (effector T cells), demon-
strating that there is not a baseline deficiency of T reg cells in
A/J animals (Fig. 3, A and B). Sorted CD4
 
 
 
CD25
 
bright
 
 T cells
had 
 
 
 
25-fold higher expression levels of Foxp3 compared
with CD4
 
 
 
CD25
 
 
 
 cells, confirming an enrichment in T reg
cells (unpublished data). After sensitization and challenge with
HDM, there is a similar four- to fivefold increase in the per-
centage of T reg cells in the lungs of both strains, again sug-
gesting that A/J and C3H mice do not differ in their ability to
recruit CD4
 
 
 
CD25
 
 
 
 cells to the site of inflammation (Fig. 3,
C and D). Finally, when the levels of T reg cells were deter-
mined in anti-CD25–treated animals, the CD4
 
 
 
CD25
 
bright
 
population was virtually eliminated in both strains of mice,
demonstrating that the anti-CD25 mAb was equally effective
in each (Fig. 3, E and F). The anti-CD25 clone 7D4 was also
used to stain cells with similar results (unpublished data). Fur-
thermore, there was no significant difference in Foxp3 expres-
Figure 3. Anti-CD25 treatment efficiently depletes T reg cells in 
A/J mice. Lung cells from C3H (A, C, and E) and A/J (B, D, and F) animals 
treated with PBS (A and B), HDM (C and D), or HDM   anti-CD25 (E and F) 
were stained with specific antibodies to CD4 and CD25 for quantification 
of CD4 CD25bright T reg cells and CD4 CD25dim effector T cells. Values indi-
cate means   SEM of frequency of CD4 CD25dim and CD4 CD25bright 
populations from groups of 16 mice. 
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sion in cells from A/J and C3H mice (P 
 
  
 
0.55), again sug-
gesting that there is no difference in T reg cell numbers in the
two strains (unpublished data). These data clearly demonstrate
that the inability of anti-CD25 treatment to enhance type 2
immunity in A/J mice is not a result of incomplete T reg cell
depletion or a lack of T reg cells in the lungs of this strain.
 
Comparison of CD4
 
 
 
CD25
 
 
 
 cell-induced suppression 
of effector T cell proliferation in A/J and C3H mice
 
The demonstration that T reg cell depletion does not enhance
the Th2 immune response in susceptible A/J mice despite simi-
lar numbers of CD4
 
 
 
CD25
 
 
 
 cells suggests that A/J mice may
possess an intrinsic defect in T reg cell suppressive capacity. To
directly examine the regulatory capacity of T reg cells from the
lungs of A/J and C3H mice, we co-cultured sorted T reg cells
(CD4
 
 
 
CD25
 
bright
 
, 
 
 
 
95% purity) from C3H or A/J mice with
carboxyfluorescein succinimidyl ester (CFSE)–labeled effector
T cells (CD4
 
 
 
CD25
 
 
 
, 99% purity) taken from the same strain
(i.e., A/J T reg cells with A/J effectors) or the opposite strain
(i.e., A/J T reg cells with C3H effectors). Both CD4
 
 
 
CD25
 
 
 
and CD4
 
 
 
CD25
 
bright
 
 T cell populations were purified from
HDM-sensitized and -challenged animals. As MHC mismatch
between A/J and C3H mice prevented the use of APCs in
these cultures, cells were stimulated with anti-CD3/CD28–
coated latex beads. When purified CD4
 
 
 
CD25
 
bright
 
 cells were
included in the cultures, there was a significant decrease in the
proliferation (Fig. 4 A) of effector T cells, demonstrating that
the CD4
 
 
 
CD25
 
bright
 
 population possesses suppressive activity
and that it was equally suppressive in A/J and C3H animals
(compare closed with light gray bars). Additionally, examination
of effector T cell cytokine production in co-culture superna-
tants revealed that CD4
 
 
 
CD25bright T reg cells isolated from the
lungs of both A/J and C3H animals have the capacity to inhibit
the synthesis of the effector T cell cytokines IL-2 and IFN- 
(Fig. 4, B and D) and IL-4 (unpublished data). CD4 CD25bright
T reg cells from the lungs do not limit effector T cell activation
by up-regulating expression of IL-10, as levels of this cytokine
were also reduced in the presence of T reg cells (Fig. 4 C). It is
also interesting to note that CD4 CD25  T cell populations
from the two strains were equally sensitive to suppression of
proliferation and cytokine synthesis by T reg cells from A/J
mice (Fig. 4, A and D, compare filled with open bars), demon-
strating that T reg cells from A/J mice are not only capable of
suppression but also that effector T cell targets are sensitive to
their suppressive influence. Similar regulatory capacity and ef-
fector T cell sensitivity in the two strains argues that CD4 
CD25  T reg cells limit the severity of AHR in C3H but not
A/J mice through influences on a non–T cell population.
T reg cell depletion during the initiation of immune 
responses is sufficient to enhance allergen-induced 
AHR in resistant C3H mice
We next determined at what stage of the immune response
the presence of T reg cells was required for limiting the de-
Figure 4. Natural CD4 CD25  T reg cells are equally functional in 
A/J and C3H animals. CD4 CD25  and CD4 CD25bright cells were puri-
fied from the lungs of HDM-sensitized and -challenged A/J or C3H mice 
and stained with CFSE. 50,000 CFSE-labeled CD4 CD25  T cells were 
co-cultured with the indicated numbers of CD4 CD25bright and stimulated 
with anti-CD3/-CD28–coated latex beads as described in Materials and 
methods. Co-cultures consisted of CD4 CD25 /CD4 CD25bright population 
from A/J/A/J, A/J/C3H, C3H/A/J, or C3H/C3H mice as indicated. TCR-   
T cells were detected via flow cytometry, and intensity of CFSE staining 
was used to identify T cells that remained undivided after 5 d of culture 
(A). Levels of IL-2 (B), IL-10 (C), or IFN-  (D) were assessed in tissue culture 
supernatant by ELISA. Data represent means   SEM. *, P   0.05 between 
cultures stimulated in the presence and absence of CD4 CD25bright.CD4 CD25  CELLS INHIBIT AIRWAY HYPERRESPONSIVENESS | Lewkowich et al. 1554
velopment of AHR in C3H mice. To this end, we adminis-
tered anti-CD25 only during induction of the immune
response (day –2), during the development of the recall im-
mune response (day 12), or throughout the allergen treat-
ment protocol (day –2 and day 12) and examined the result-
ing allergic responses. As previously demonstrated, treatment
of C3H mice with anti-CD25 throughout the course of the
experiment results in enhanced AHR (Figs. 1 D and 5 A).
Treatment of mice with anti-CD25 before the initiation of
the immune response was sufficient to increase AHR to lev-
els similar to that seen in mice receiving anti-CD25 treat-
ment throughout (Fig. 5 A). Similar results were found for
BAL eosinophilia: a single dose of anti-CD25 before sensiti-
zation enhanced eosinophil counts to a level indistinguish-
able from those seen in mice receiving anti-CD25 throughout
(Fig. 5 C). In contrast, treatment of mice with only anti-
CD25 during the effector phase of the immune response did
not significantly enhance AHR or BALF cellularity compared
with mice receiving the isotype control mAbs (Fig. 5, A–C).
To examine the intensity of the type 2 immune response,
production of Th2 cytokines was examined in HDM-stimu-
lated whole lung cell cultures from mice that received treat-
ment with anti-CD25 before the initiation of the immune
response, during the effector phase, or throughout the exper-
iment. HDM-stimulated type 2 cytokine production in mice
depleted of T reg cells during the initiation of the immune
Figure 5. T reg cell depletion during initiation of immune 
response is sufficient to exacerbate AHR. C3H mice were treated with 
PBS or HDM as in Materials and methods. HDM-treated mice were treated 
with isotype/isotype (Iso Iso), aCD25/isotype (anti-CD25 Iso), isotype/
anti-CD25 (Iso aCD25), or anti-CD25/anti-CD25 (aCD25 aCD25) during the 
initiation and effector phases, respectively. AHR (A) to i.v. acetylcholine was 
assessed before death, 72 h after final HDM challenge. BALF was harvested 
at time of death and total BAL cells (B) and differential cell counts (C) were 
performed. Lung cells from the indicated groups were cultured in the 
presence of 30  g/ml HDM, and tissue culture supernatants were 
harvested after 72 h to determine production of IL-4 (D), IL-5 (E), IL-10 
(F), and IL-13 (G). Data represent means   SEM (n   12 mice/group). 
† or ††, P   0.05 or P   0.001, respectively, compared with HDM Iso/Iso–
treated animals.JEM VOL. 202, December 5, 2005 1555
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response was indistinguishable or, in the case of IL-4, slightly
elevated compared with cultures from mice given anti-CD25
throughout the experiment (Fig. 5, D–G). In contrast, cul-
tures of HDM-stimulated lung cells from mice treated with
anti-CD25 during the effector phase of the immune response
did not consistently produce more cytokines compared with
those treated with isotype control antibodies (Fig. 5, D–G).
Although administration of anti-CD25 mAb during the ef-
fector phase of the immune response consistently failed to
enhance the intensity of airway responses or cytokine pro-
duction, it is important to point out that treatment with anti-
CD25 also failed to diminish any features of the allergic phe-
notype as expected if anti-CD25 treatment was depleting
CD25  effector T cells. This confirms that the CD25bright
population depleted after anti-CD25 administration consists
primarily of natural Foxp3  T reg cells, as reported elsewhere
(12). Collectively, these data demonstrate that in our model
of HDM-stimulated experimental asthma, the principal en-
dogenous controls that limit the development of allergen-
induced AHR in naturally resistant hosts occur very early in
the immune response and not at the effector T cell level.
Depletion of T reg cells increases the frequency 
of immunogenic pulmonary DCs
The data in Fig. 5 demonstrate that T reg cell–mediated sup-
pression after initiation of the immune response is not re-
quired to control AHR in C3H mice. Because DCs are
known for their ability to initiate an immune response and
pulmonary DCs have potent antigen-presenting capacity
(19), we assessed the impact of anti-CD25 treatment on the
numbers and phenotype of DCs found in the lung after aller-
gen challenge. We were particularly interested in plasmacy-
toid DCs (pDCs [CD11c , CD11b , Gr1 , and B220 ])
and mDCs (CD11c , CD11b , Gr1 , and B220 ), as these
subsets had been ascribed immunosuppressive and immuno-
stimulatory roles, respectively, in experimental asthma mod-
els (20). Compared with PBS-treated C3H mice, HDM-
challenged C3H mice treated with control mAbs displayed a
fivefold increase in the number of both pulmonary mDCs
and pDCs after HDM sensitization/challenge (Fig. 6). Treat-
ment with anti-CD25 before the initiation of the immune
response or throughout the entire treatment protocol further
increased the number (Fig. 6 A) and frequency (Fig. 6 B) of
mDCs found in the lungs of HDM-exposed C3H mice. In
contrast, when T reg cell depletion was delayed until the
effector phase, the anti-CD25–induced increase in mDC
number and frequency was completely abrogated (Fig. 6, A
and B). Interestingly, treatment with anti-CD25, particularly
during the effector phase, resulted in a decrease in the num-
ber and frequency of pDCs found in the lung to levels simi-
lar to those seen in naive mice (Fig. 6, C and D). In contrast,
anti-CD25 treatment of A/J mice did not significantly in-
crease the number of mDCs (556,776   69,067 vs. 571,492  
74,718 for Iso/Iso- and anti-CD25/anti-CD25–treated A/J
mice, respectively) or significantly decrease the number of
pDCs (26,268   2,082 vs. 29,556   2,992 for Iso/Iso- and
anti-CD25/anti-CD25–treated A/J mice, respectively) in the
lungs of HDM-sensitized and -challenged mice. Thus, al-
though natural T reg cells limit the number of immunogenic
mDCs in the lungs of resistant hosts, pulmonary DCs from
normally susceptible animals appear refractory to similar T
reg cell–mediated suppression.
Pulmonary DCs from anti-CD25–treated animals have 
elevated expression of co-stimulatory molecules
As DC expression of ICOS-L or PD-L1/PD-L2 facilitates
down-regulation of T cell activity by signaling through T
cell–expressed ICOS or PD-1 (8, 21), we hypothesized that
reduced expression of these coinhibitory molecules may
promote the enhanced asthmatic phenotype observed after T
reg cell depletion in C3H mice. However, treatment with
anti-CD25 did not significantly decrease HDM-induced
ICOS-L (mDC, P   0.89; pDC, P   0.97), PD-L1 (mDC,
P   0.36; pDC, P   0.69), or PD-L2 (mDC, P   0.21;
pDC, P   0.96) expression on mDC or pDC populations
(unpublished data). Although the frequency of ICOS  T
cells did decrease as a result of anti-CD25 treatment, the re-
maining T cells expressing ICOS had a greater level of ex-
pression on a per-cell basis (unpublished data). The failure
of anti-CD25 treatment to consistently alter expression of
ICOS/ICOS-L or PD-L1/PD-L2/PD-1 family members
led us to conclude that these pathways were not of critical
importance in our model system.
We next examined the T cell stimulatory capacity of pul-
monary DCs taken from anti-CD25– or isotype-treated aller-
gen-primed C3H mice. To this end, expression of MHC class
II, CD80, and CD86 were examined on pulmonary mDC
and pDC subsets by flow cytometry in mice treated with anti-
Figure 6. T reg cell depletion before HDM sensitization increases 
the frequency of pulmonary mDCs. Mice were treated as in Fig. 5. Total 
number (A) and frequency (as a function of total lung cells) of mDCs 
(CD11c , CD11b , Gr1 ; B) and total number (C) and frequency (as a 
function of total lung cells; D) of pDCs (CD11c , CD11b , Gr1 ) were 
determined by flow cytometry. Data represent means   SEM (n   12 
mice/group). † or ††, P   0.05 or P   0.001, respectively, compared with 
HDM Iso/Iso–treated animals.CD4 CD25  CELLS INHIBIT AIRWAY HYPERRESPONSIVENESS | Lewkowich et al. 1556
CD25 before the initiation of the immune response, during
the effector phase, or both. As shown in Fig. 7 A, compared
with PBS-treated control C3H mice, the frequency of
CD80-, CD86-, and MHC class II–expressing mDCs (as a
function of total lung cells) was significantly increased in
mice treated with HDM and control mAb. Interestingly, con-
comitant with observed increases in AHR, expression of all
three co-stimulatory molecules examined was significantly in-
creased only in mice that received anti-CD25 before the initi-
ation of the immune response (Fig. 7 A). In contrast, mice
treated with only anti-CD25 during the effector phase of the
immune response demonstrated no appreciable change in the
frequency of CD80 , CD86 , or MHC class II  mDCs (Fig.
7 A). The frequency of pulmonary pDC expression of MHC
class II, CD80, and CD86 was not significantly affected by
HDM treatment, and though there was a trend toward de-
creased pDC expression of CD80, CD86, and MHC class II
in mice receiving anti-CD25 treatment throughout the pro-
tocol, this did not reach statistical significance (Fig. 7 B). It is
important to stress that even though the increases in the fre-
quency of CD80/86/MHC class II–expressing mDCs appears
minor in the context of total lung cells, a 0.1% increase in fre-
quency (as seen in CD80  mDCs in anti-CD25/Iso–treated
mice compared with Iso/Iso-treated mice) represents as many
as 60,000 CD80  mDCs. It is also important to note that ex-
pression of CD25 was not detectable on any subset of DCs
(unpublished data), and, thus, alterations of pDC or mDC
numbers are not caused by direct effects of the mAb. These
data demonstrate that changes in DC phenotype and stimula-
tory capacity are strongly correlated with enhanced airway
and cytokine responses seen after T reg cell depletion in natu-
rally resistant mice.
Pulmonary DCs from anti-CD25–treated C3H mice have 
increased T cell stimulatory capacity
The fact that T reg cell depletion increases the numbers of
mDCs and their expression of antigen-presenting and co-stim-
ulatory molecules suggests that perhaps T reg cells regulate the
immunostimulatory capacity of DCs. To directly test this hy-
pothesis, we purified CD11c  DCs from the lungs of isotype
control– or anti-CD25–treated HDM-sensitized mice 72 h af-
ter the final HDM challenge. Purified DCs were co-cultured
with CFSE-labeled lung T cells (from mice treated with
HDM alone, 72 h after final challenge) at various DC/T cell
ratios, and the resultant T cell proliferation and cytokine pro-
duction was quantified. As shown in Fig. 8 A, the number of
undivided T cells in C3H cultures stimulated with DCs from
anti-CD25–treated animals was significantly lower than that
seen in cultures stimulated with DCs from isotype-treated ani-
mals. In contrast, anti-CD25 treatment of A/J mice does not
result in a population of DCs that demonstrate increased T cell
stimulatory capacity (Fig. 8 B). When T cell cytokine pro-
duction was examined in DC/T cell co-cultures from anti-
CD25–treated C3H mice (1:1 ratio), there was a substantial
increase in the production of IL-4 (55%), IL-5 (42%), IL-10
(58%), and IL-13 (38%) and a small but significant increase in
IL-2 (15%) synthesis (Fig. 8 C). Cytokine production in cul-
tures stimulated with DCs from anti-CD25–treated A/J mice
was identical to that seen in cultures stimulated with DCs from
isotype-treated A/J mice (Fig. 8 D). IFN-  was not produced
in detectable quantities in any culture (unpublished data).
To further explore potential mechanisms through which
T reg cell–DC interactions may limit the development of
AHR, we focused on indoleamine 2,3-dioxygenase (IDO)
(22), an enzyme implicated in negative regulation of T cell
Figure 7. Depletion of CD4 CD25  cells during the initiation of the 
immune responses increases the frequency of MHC class II, CD80, and 
CD86 expression mDCs. Mice were treated as in Fig. 5. Frequency (as a 
function of total lung cells) of CD80-, CD86-, and MHC class II–expressing 
mDCs (A) and pDCs (B) were determined by flow cytometry. Data repre-
sent means   SEM (n   12 mice/group). † or ††, P   0.05 or P   0.001, 
respectively, compared with HDM Iso/Iso–treated animals.JEM VOL. 202, December 5, 2005 1557
ARTICLE
activation (23). By adding the IDO inhibitor 1-methyl-DL-
tryptophan to the DC/T cell co-cultures described above,
we found that inhibition of IDO activity did not signifi-
cantly alter the capacity of pulmonary DCs from isotype- or
anti-CD25–treated animals to stimulate T cell proliferation.
These data suggest that activity of this enzyme in pulmonary
DCs is not significantly altered by T reg cell depletion. In
contrast, the expression of IL-12 p40, a DC-derived cyto-
kine involved in limiting the development of AHR in resis-
tant C3H mice (24), was significantly lower ( 50%) in DCs
isolated from anti-CD25–treated C3H mice as compared
with levels seen in DCs from isotype-treated animals (Fig. 8
F). Similar inhibition of IL-12 p40 expression was not seen
in anti-CD25–treated A/J mice (unpublished data). Thus,
depletion of T reg cells in resistant animals does not di-
minish the activity of regulatory enzymes (like IDO), but
rather renders pulmonary DCs less capable of limiting the
development of a Th2-dominated immune response by
limiting their capacity to produce IL-12. These data sug-
gest that there are regulatory influences exerted by natural T
reg cells on DCs that are unique to those hosts resistant to
the development of AHR.
DISCUSSION
Although the role of naturally occurring T reg cells in con-
trol of autoimmune disease is becoming increasingly appar-
ent, their potential involvement in limiting the development
of allergic asthma remains poorly understood. In this paper,
we examined the role that natural T reg cells play in limiting
the development of AHR by comparing the impact of
CD4 CD25  T reg cell depletion on airway responses in A/J
(susceptible to development of AHR after allergen expo-
sure) with C3H mice (resistant to development of AHR
after allergen exposure). We demonstrate that depletion of
CD4 CD25  T cells significantly enhances AHR, airway
inflammation, Th2 cytokine production, and in vivo IgE
synthesis in C3H but not A/J animals. Interestingly, the
results of our study suggests that naturally occurring CD4 
Figure 8. T reg cell depletion enhances the T cell stimulatory 
capacity of pulmonary DCs from C3H but not A/J mice. CD11c  DCs 
with low autofluorescence were sorted from lungs of isotype-treated 
(closed squares and bars) or anti-CD25–treated (open circles and bars) 
HDM-sensitized/challenged mice. DCs were co-cultured at the indicated 
ratios with CFSE-labeled CD4  T cells purified from the lungs of HDM-
sensitized/challenged mice in the presence of 30  g/ml HDM. The 
frequency of undivided T cells was determined after 3 d of co-culture via 
flow cytometry in cultures from C3H (A) and A/J (B) mice. Cytokine levels 
in HDM-stimulated DC/T cell co-cultures (1:1) from C3H (C) and A/J (D) 
mice. (E) The effect of IDO inhibition in DC/T cell co-cultures was assessed 
by inclusion of 1-methyl-DL-tryptophan in co-cultures from isotype- and 
anti-CD25–treated C3H mice. (F) IL-12 p40 expression was examined in 
DCs purified from C3H mice as described above. Data represent means   
SEM (n   8 mice/group). * or **, P   0.05 or P   0.001, respectively, com-
pared with cultures containing DCs from HDM Iso/Iso–treated animals.CD4 CD25  CELLS INHIBIT AIRWAY HYPERRESPONSIVENESS | Lewkowich et al. 1558
CD25  T reg cells normally limit the development of AHR
in resistant hosts by limiting expression of CD80, CD86, and
MHC class II while promoting IL-12 production in pulmo-
nary DCs, thereby preventing T cell proliferation and Th2
cytokine production. Furthermore, these data suggest that
natural CD4 CD25  T reg cells function through mecha-
nisms distinct from antigen-inducible T reg cells and that
failure of T reg cells to limit DC activation in normally sus-
ceptible animals contributes to the development of allergen-
induced AHR.
We demonstrate that depletion of CD4 CD25  T cells
using an mAb to CD25 results in a significant enhancement
of airway eosinophilia (Fig. 1 B), in vivo IgE synthesis (Fig.
2, A and B), and Th2 cytokine production (Fig. 2, C–F) in
naturally resistant C3H mice. Consistent with increased in-
tensity of type 2 immunity and increased airway eosino-
philia, we also observed significant increases in AHR after
depletion of CD4 CD25  T reg cells. In contrast, despite
dramatic reductions in the number of CD4 CD25  T reg
cells found in the lung (Fig. 3 F), similar treatment of suscep-
tible A/J animals resulted in only a modest increase in airway
eosinophilia (Fig. 1 D) without concomitant enhancement
of AHR, type 2 cytokine production, or IgE serum levels
(Fig. 2, A–F). Our findings are consistent with studies con-
ducted in other asthma-prone murine strains, such as BALB/
c, in which T reg cells were also shown to limit eosinophilia
but not type 2 cytokine production or AHR (13, 14). Col-
lectively, these results suggest that naturally occurring T reg
cells have different levels of activity in hosts that are suscepti-
ble and resistant to the development of asthma. Consistent
with this concept, recent experiments conducted in human
subjects show that, compared with healthy controls, atopic
subjects possessed reduced T reg cell numbers or defects in T
reg cell function, demonstrating that allergy is accompanied
by defects in the regulatory capacity of the host (25, 26).
One caveat to our study, as well as others using anti-
CD25 to identify natural T reg cell populations, is that
CD25 and other markers commonly used to identify T reg
cells (ICOS, GITR, and CD103) are also expressed on re-
cently activated effector T cells, making it impossible to rule
out the possibility that effects of the mAb relate to depletion
of activated T cells. However, the anti-CD25 mAb (PC61)
used in our experiments has been used in other studies to
transiently deplete T reg cells in vivo (17, 18, 27). Further-
more, the increased intensity of the immune response ob-
served in C3H mice and, to a lesser extent, in A/J animals
after administration of anti-CD25 is more consistent with
the removal of a negative regulatory population than deple-
tion of an effector T cell population. Interestingly, the anti-
CD25 mAb used selectively depleted those cells expressing
the highest levels of CD25 (Fig. 3, E and F), a population re-
cently demonstrated to comprise primarily Foxp3  cells (12,
28). As Foxp3 expression remains the most specific T reg
cell marker identified to date and indeed confers regulatory
capacity (12, 28), it seems likely that the anti-CD25 adminis-
tration in this model depletes T reg and not effector T cells.
It is generally thought that T reg cell–mediated suppres-
sion of immune responses occurs at the level of the effector
T cell either through regulation of IL-2 production by target
T cell populations and/or expression of IL-10, CTLA-4
and/or TGF-  (29–32). Our data suggest, however, that
natural T reg cells do not limit the development of AHR in
resistant animals through interactions with effector T cells.
This is supported by the following observations: (a) despite
the dramatically different outcomes of T reg cell ablation in
vivo in A/J and C3H mice, these mice do not markedly dif-
fer in either the suppressive capacity of their respective T reg
cells or the sensitivity of their effector T cells to T reg cell–
mediated suppression (Fig. 4); (b) in C3H mice, T reg cell
depletion during the effector phase of the immune response
fails to increase AHR, whereas depletion before the initia-
tion of the immune response results in substantial increases in
AHR (Fig. 5 A); and (c) pulmonary DCs purified from anti-
CD25–treated C3H mice stimulate a greater level of T cell
proliferation and cytokine production than those taken from
mice with an intact T reg cell compartment (Fig. 8, A and
C). Furthermore, we find increased IL-10 production after T
reg cell depletion (Fig. 2 C) and no correlation between the
observed changes in ICOS/ICOS-L (unpublished data) and
the changes in AHR after T reg cell depletion (Fig. 5 A).
This suggests that the effects of T reg cells in our model are
not mediated through IL-10– or ICOS/ICOS-L–dependent
pathways, as has been previously reported for T reg cells in-
duced by exposure to mucosally administered allergen or ex-
posure to bacterial products (8, 10, 11). These differences
may reflect distinct roles of natural and inducible T reg cells
(i.e., Tr1 or Tr3) in regulating immune responses in vivo.
In examining the impact of T reg cell depletion on pul-
monary DC populations, several important observations were
made. First, we demonstrate that T reg cell depletion before
initiation of the immune response, but not during the effec-
tor phase, results in an increase in the number of pulmonary
mDCs (Fig. 6, A and B). These changes in the frequency of
mDCs correlate well with observed changes in AHR after
anti-CD25 administration (Fig. 5 A). A recent study by de
Heer et al. demonstrated that in murine models of allergic
asthma, mDCs were particularly immunogenic in murine,
whereas pDCs promoted tolerance to allergen exposure (20).
Thus, the observed shift toward increased frequency of
mDCs in the lungs of anti-CD25–treated C3H mice repre-
sents the development of a highly immunogenic population
of pulmonary DCs. Indeed, when the T cell stimulatory ca-
pacity of pulmonary DCs was examined, it was determined
that T reg cell depletion enhanced the ability of DCs from
C3H but not A/J animals to stimulate T cell proliferation
and cytokine production (Fig. 8). Furthermore, enhanced
expression of classical co-stimulatory molecules as a result
of anti-CD25 treatment was confirmed by the observation
of significantly enhanced expression of MHC class II,
CD80, and CD86 in C3H mice depleted of natural T reg
cells (Fig. 7 A). Similar negative regulation of MHC class II
and CD80/CD86 expression by T cells has been observedJEM VOL. 202, December 5, 2005 1559
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when anergic T cells or T cells taken from cardiac allograft–
tolerant mice were co-cultured with Ag-pulsed DCs (33,
34). Moreover, natural CD4 CD25  T reg cells isolated
from naive mice directly regulate DC expression of CD80
(by down-regulating CD80 mRNA levels) and CD86
(through unknown mechanisms) in a contact-dependent
mechanism (35).
Although we cannot yet identify the precise mechanism
by which T reg cells negatively regulate the phenotype and
activation state of DCs, our results indicate that this regula-
tion does not occur at the level of IDO activity (Fig. 8 E) in
our model, as suggested elsewhere (22). Interestingly, our
data do support a role for T reg cells in promoting the pro-
duction of IL-12, as DC populations from T reg cell–
depleted mice demonstrated reduced IL-12 p40 mRNA lev-
els (Fig. 8F). Reduced IL-12 availability in “susceptible” C3H
mice after T reg cell depletion is wholly consistent with our
previous report demonstrating that IL-12 neutralization is
sufficient to trigger robust airway responses in C3H mice
(24). Although we are unaware of any report of direct T reg
cell regulation of DC IL-12 synthesis, T reg cells do enhance
DC IFN-  production (22), and IFN-  enhances IL-12 p40
expression (36), suggesting a potential mechanism by which
T reg cells may promote IL-12 production. Although the
observation of reduced IL-12 production is sufficient to en-
hance airway responses in resistant mice, we are presently
unable to ascertain whether reducing IL-12 synthesis repre-
sents the specific mechanism by which T reg cells influence
DC activation or whether depressed IL-12 p40 expression is
a manifestation of other regulatory influences. Moreover,
the lack of effect of T reg cell depletion on DC activation
and p40 production in the susceptible strain may represent
an inability of endogenous CD4 CD25  T reg cells to limit
DC activation or refractoriness of the DCs to the inhibitory
effects of T reg cells. Further studies are required to elucidate
the exact mechanisms underlying these genetic differences.
In summary, the findings reported here demonstrate that
naturally occurring T reg cells play a major role in conferring
natural resistance to the development of allergen-induced
AHR. Moreover, our findings highlight a novel mechanism
by which T reg cells exert their regulatory control on the al-
lergic response, that of controlling DC activation and anti-
gen presentation rather than through direct effects on effec-
tor T cells. Collectively, these results provide support for the
hypothesis that development of allergic asthma may be a re-
sult of an inefficient regulatory network, one of the central
tenets of the hygiene hypothesis (37, 38). Accordingly, these
findings suggest that modulation of this pathway may pro-
vide an effective means of controlling aberrant immune re-
sponses to harmless airborne antigens.
MATERIALS AND METHODS
Mice. 5–6-wk-old male A/J and C3H/HeJ mice were purchased from the
Jackson Laboratory and housed in a specific pathogen-free facility at Cin-
cinnati Children’s Hospital Medical Center. Cincinnati Children’s Hospital
Medical Center Institutional Animal Care and Use Committee approved all
animal studies.
Characterization of allergen-induced asthma phenotype. A/J and
C3H mice were given 100  g HDM extract (Greer Laboratories) or 40  l
PBS i.t. on days 0, 14, and 21. To deplete T reg cells in vivo, mice were
treated with 1 mg anti-CD25 (mAb PC61) or a rat IgG1 isotype control
(mAb GL113; a gift of F. Finkelman, Cincinnati Children’s Hospital, Cin-
cinnati, OH) administered i.p. on day –2 and/or day 12. To evaluate airway
responses, mice were anaesthetized, intubated, and respirated at a rate of
120 breaths per minute with a constant tidal volume (0.2 ml) and paralyzed
with 25 mg/kg decamethonium bromide 72 h after final allergen challenge.
After a stable baseline was achieved, 50 mg/kg acetylcholine was injected
into the inferior vena cava, and dynamic airway pressure (cm H2O   sec)
was followed for 5 min. Immediately after AHR measurements, blood was
collected. Serum samples were tested for total and HDM-specific IgE using
antibodies from BD Biosciences. To collect BALF, lungs were lavaged three
times with a 1.0-ml aliquot of cold Hanks’ balanced salt solution (Invitro-
gen). Recovered lavage fluid (70–80%) was centrifuged at 300 g for 8 min,
and the cell pellet was resuspended in 1.0 ml of 10% FBS in PBS. Total cells
were counted with a hemocytometer (Hauser Scientific). Slides were pre-
pared by cytocentrifugation (Cytospin 3; Shandon Instruments) and stained
with Diff-Quik (Dade Behring). BAL cell differential counts were deter-
mined using morphologic criteria under a light microscope (Optical Ele-
ments Corporation) with the evaluation of  500 cells/slide.
Lung cell isolation. After collection of BAL, lungs were perfused with 5
ml of ice-cold PBS and removed. Lungs were minced and placed in 6 ml
RPMI 1640 containing 0.5 mg/ml Liberase CI (Roche Diagnostics) and
0.5 mg/ml DNase I (Sigma-Aldrich) and incubated at 37 C for 45 min. To
make a single cell suspension, the remaining tissue was forced through a 70-
 m cell strainer. Cells were pelleted and red blood cells were lysed using 1
ml of ACK lysis buffer (Biosource International). The remaining cells were
washed with RPMI 1640 containing 10% FBS, and viable cells were
counted via trypan blue exclusion and used in subsequent experiments.
Cells were cultured at 8.3   105 cells/ml in a total volume of 300  l. Cells
were stimulated with culture medium alone or HDM at 30  g/ml. Tissue
culture supernatant was harvested at 72 h and frozen at –70 C until cyto-
kine concentrations were assayed.
Determination of cytokine concentration. Cytokine levels in lung cell
culture supernatants were measured by ELISA using matched antibody pairs
purchased from BD Biosciences (IL-4 and IL-5) or R&D Systems (IL-10
and IL-13). Cytokine concentrations in tissue culture supernatants from
DC/T cell co-cultures were measured using a Bio-Plex suspension array sys-
tem (Bio-Rad Laboratories). Multiplex assay kits were purchased from Bio-
source International and used according to the manufacturer’s instructions.
Flow cytometry. Staining reactions were performed at 4 C after incuba-
tion of cells with anti-CD16/32 mAb (clone 2.4G2) for 30 min. mDCs
(CD11c , CD11b , and Gr1 ) and pDCs (CD11c , CD11b , and Gr1 )
were quantified using antibodies to CD11c (HL3), CD11b (M1/70), and
Gr1 (RB6-8C5). Co-stimulatory molecule expression was examined by us-
ing antibodies to CD80 (16-10A1), CD86 (GL1), MHC class II I-Ek (14-4-
4s), ICOS-L (HK5.3), B7-H1 (MIH5), and B7-DC (TY25). T cell subsets
were examined using mAbs to CD4 (RM4-5), CD25 (PC61 or 7D4), and
ICOS (7E.17G9), and proliferation was followed using CFSE (Invitrogen).
Dead cells were excluded using the viability dye 7-amino-actinomycin D
(7-AAD). All antibodies were purchased from BD Biosciences or eBioscience.
All samples were analyzed for six colors using a FACSVantage SE flow cy-
tometer equipped with 488-nm argon and 633-nm HeNe lasers and digital
DiVa software. Spectral overlap was compensated using the DiVa software
(BD Biosciences). Analysis was done using FlowJo software (Tree Star, Inc.).
T reg cell inhibition assay. The capacity of T reg cells from A/J and
C3H mice to inhibit proliferation of T effectors from A/J and/or C3H mice
was determined using an in vitro assay. Lungs of HDM-sensitized and -chal-
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ulations were sorted using a FACSVantage SE. T reg cells were defined as
CD4 CD25bright, and effector T cells were defined as CD4 CD25 . Purified
cells were  95 and 99% pure, respectively. 105 CD4 CD25  effectors were
stained with CFSE and cultured in 96-well U-bottom plates with CD4 
CD25bright T reg cells at the ratios indicated in the figures. To avoid using
APCs in these cultures (because of A/J–C3H MHC mismatch), cultures
were stimulated with nothing or 5- m latex beads (105 beads/well; Interfa-
cial Dynamics Corporation) coated with anti-CD3 (145-2C11) and anti-
CD28 (37.51). Cells were harvested after 3 d, and the proliferation index was
determined based on CFSE dilution using FlowJo.
DC/T cell co-culture. The ability of purified pulmonary DCs to stimu-
late effector T cell proliferation and cytokine production was determined
using an in vitro assay. CD11c  7-AAD  cells were purified from HDM-
sensitized mice treated with isotype- or anti-CD25–treated A/J and C3H
mice 72 h after final HDM exposure using a FACSVantage SE. To remove
contaminating alveolar macrophages, which also express CD11c, cells with
low autofluorescence in FL1 were then purified as previously described
(39). The resulting population was  95% CD11c , and 85% had low au-
tofluorescence. CD4  T cells were purified from the lungs of HDM-sensi-
tized A/J or C3H animals ( 99% purity). 5   104 T cells labeled with
CFSE were cultured with varying numbers of purified DCs in the presence
of 30  g/ml HDM. Cells were harvested after 3 d of culture, and CFSE di-
lution was used to determine the degree of proliferation of TCR-  CD4 
T cells using FlowJo. Day 3 tissue culture supernatants were frozen at
–80 C for determination of T cell cytokine production.
Quantitative real-time RT-PCR. To measure IL-12 p40 and IDO mes-
sage expression in flow cytometry–purified pulmonary DCs isolated from
isotype- or anti-CD25–treated, HDM-sensitized and -challenged A/J and
C3H mice, we used quantitative RT-PCR assays as described previously
(40). PCR primer pairs were designed using Beacon Designer software (Pre-
mier Biosoft International) and were as follows: IL-12 p40 sense, CAG-
AAGCTAACCATCTCCTGG, and IL-12 p40 anti-sense, TCAGGCGT-
GTCACAGGTGAG.
Statistical analysis. For comparison between multiple groups, one-way
analysis of variance was used to determine differences between groups with
post hoc comparisons using Fisher’s method. For comparison between two
groups, Student’s t test was performed. In both cases, significance was assumed
at P   0.05.
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